Johnson & Johnson (JNJ) 105.80 $JNJ
India Coronary Stent Market-Potentials and Growth Forecast to 2019 with Abbott Vascular & Boston Scientific Leading the Way
M2 - 1 hr 32 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hwfcwx/india_coronary) has announced the addition of the "India Coronary Stent Market-Potentials and Growth Forecast to 2019" report to their offering. India Coronary Stent Market Would Continue to Grow in Double Digits and Abbott Vascular to Lead the Market The coronary stent market in India was valued around $450 million in 2012 and it has grown at an impressive rate of 22% (2005-2012) backed by a rise in PCIs (Percutaneous Coronary Intervention) which is resulted from a surge in cardiovascular disease (CVD), an improvement in healthcare infrastructure and services and an increase in disposable income. An increasing penetration of DES, which is above 90%, has also boosted the market. The market is lead by Abbott Vascular, followed by Boston Scientific. Other key players operating in the segment are Medtronic, Inc., Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics. Johnson and Johnson's Cordis stopped selling its stents from 20011. Cordis's market was grabbed by Abbott, Medtronic and other players. Bioabsorbable stent ABSORB, which was recently launched by Abbott Vascular, has garnered a considerable traction among the medical fraternity despite its high cost compared with other stents available in the market. The patients opting for ABSORB are financially sound or have either health insurance or are entitled for reimbursement. Abbott is aggressively chasing the market through a direct-to-consumer approach (DTC). The coronary stent market in the country will continue to grow at a faster pace due to new and upcoming private hospitals, government initiatives to improve healthcare access, an increasing number of interventional cardiologists, an explosion of healthcare insurance and a growth in usage of high value bioabsorbable stents. The anticipated progression can be attributed to growth in elderly population, improved life expectancy, lifestyle diseases and associated complications like diabetes, hypertension and obesity. Companies Mentioned - Abbott Vascular - Boston Scientific Corporation - Medtronic, Inc. - Biotronik - SMTPL - Meril Life Sciences - Translumina Therapeutics For more information visit http://www.researchandmarkets.com/research/hw...a_coronary
Sanofi/Regeneron Announce Encouraging Dupilumab Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:30PM CDT
Sanofi (SNY) and partner Regeneron Pharmaceuticals (REGN) announced positive results from a phase IIb study on dupilumab.
Is This Huge Market Slowing Down?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Jul 10, 1:00PM CDT
Waiting for a recovery in the orthopedic market isn't exactly waiting for Godot, but it has been frustrating all the same. Between modest (but steady) price pressure, lower patient volumes, and more assertive hospital customers, major ortho companies...
Midday Glance: Pharmaceuticals companies
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
Early Glance: Pharmaceuticals companies
AP - Thu Jul 10, 10:01AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu Jul 10, 10:01AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
'Mad Money' Lightning Round: AT&T Is a Buy
at The Street - Thu Jul 10, 5:00AM CDT
Cramer wants to own WhiteWave Foods, likes Johnson & Johnson over Pfizer and wants you to stay away from Gogo.
New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo
PR Newswire - Thu Jul 10, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4619-100free.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Is Pharmacyclics the Next Celgene?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica, a drug being co-developed with Johnson & Johnson that won its first FDA approval last November. Imbruvica...
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Will Fastenal (FAST) Beat Earnings Estimate in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:00AM CDT
Fastenal Company (FAST) is set to report second-quarter fiscal 2014 results on Jul 11, before the market opens.
Global Electrophysiology Ablation Catheters Market 2014-2018
M2 - Wed Jul 09, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpds69/global) has announced the addition of the "Global Electrophysiology Ablation Catheters Market 2014-2018" report to their offering. Catheter ablation is a minimally invasive procedure used to remove or destroy faulty electrical pathways from sections of the heart that promote irregular cardiac rhythms (also known as cardiac arrhythmias). Cardiac arrhythmias can be of several types, including atrial fibrillation, atrial flutter, and supraventricular tachycardia. Key Regions: - Americas - EMEA - APAC Key Vendors: - Boston Scientific Corp. - Johnson & Johnson - Medtronic Inc. - St. Jude Medical Inc. Other Prominent Vendors: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - VIMECON GmbH Key Market Drivers: - Growing Incidence of Cardiac Arrhythmias. - For a full, detailed list, view the report. Key Market Challenges: - Presence of Substitutes. - For a full, detailed list, view the report. Key Market Trends: - High Adoption of Irrigated-tip EP Ablation Catheters. - For a full, detailed list, view the report. Key Questions Answered in this Report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - Boston Scientific Corp. - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - Johnson & Johnson - Medtronic Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - St. Jude Medical Inc. - VIMECON GmbH For more information visit http://www.researchandmarkets.com/research/zpds69/global
Fortune 500 Companies Recruit Talent at CAREERS & the disABLED Magazine's Career Expo
PR Newswire - Tue Jul 08, 1:01PM CDT
Equal Opportunity Publications, Inc. (EOP), the leading publisher of diversity recruitment print and online magazines, announces registration is open for CAREERS & the disABLED Magazine's Career Expo, July 18 at the Wyndham New Yorker Hotel in New York City, from 10 a.m. to 3 p.m.
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
India Coronary Stent Market-Potentials and Growth Forecast to 2019 with Abbott Vascular & Boston Scientific Leading the Way
M2 - 1 hr 32 mins ago
Research and Markets (http://www.researchandmarkets.com/research/hwfcwx/india_coronary) has announced the addition of the "India Coronary Stent Market-Potentials and Growth Forecast to 2019" report to their offering. India Coronary Stent Market Would Continue to Grow in Double Digits and Abbott Vascular to Lead the Market The coronary stent market in India was valued around $450 million in 2012 and it has grown at an impressive rate of 22% (2005-2012) backed by a rise in PCIs (Percutaneous Coronary Intervention) which is resulted from a surge in cardiovascular disease (CVD), an improvement in healthcare infrastructure and services and an increase in disposable income. An increasing penetration of DES, which is above 90%, has also boosted the market. The market is lead by Abbott Vascular, followed by Boston Scientific. Other key players operating in the segment are Medtronic, Inc., Biotronik, Sahajanand Medical Technologies, Meril Life Sciences and Translumina Therapeutics. Johnson and Johnson's Cordis stopped selling its stents from 20011. Cordis's market was grabbed by Abbott, Medtronic and other players. Bioabsorbable stent ABSORB, which was recently launched by Abbott Vascular, has garnered a considerable traction among the medical fraternity despite its high cost compared with other stents available in the market. The patients opting for ABSORB are financially sound or have either health insurance or are entitled for reimbursement. Abbott is aggressively chasing the market through a direct-to-consumer approach (DTC). The coronary stent market in the country will continue to grow at a faster pace due to new and upcoming private hospitals, government initiatives to improve healthcare access, an increasing number of interventional cardiologists, an explosion of healthcare insurance and a growth in usage of high value bioabsorbable stents. The anticipated progression can be attributed to growth in elderly population, improved life expectancy, lifestyle diseases and associated complications like diabetes, hypertension and obesity. Companies Mentioned - Abbott Vascular - Boston Scientific Corporation - Medtronic, Inc. - Biotronik - SMTPL - Meril Life Sciences - Translumina Therapeutics For more information visit http://www.researchandmarkets.com/research/hw...a_coronary
Sanofi/Regeneron Announce Encouraging Dupilumab Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 3:30PM CDT
Sanofi (SNY) and partner Regeneron Pharmaceuticals (REGN) announced positive results from a phase IIb study on dupilumab.
Is This Huge Market Slowing Down?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Thu Jul 10, 1:00PM CDT
Waiting for a recovery in the orthopedic market isn't exactly waiting for Godot, but it has been frustrating all the same. Between modest (but steady) price pressure, lower patient volumes, and more assertive hospital customers, major ortho companies...
Midday Glance: Pharmaceuticals companies
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Thu Jul 10, 12:44PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
Early Glance: Pharmaceuticals companies
AP - Thu Jul 10, 10:01AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Early Glance: Medical Devices companies
AP - Thu Jul 10, 10:01AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are down at 10 a.m.:
'Mad Money' Lightning Round: AT&T Is a Buy
at The Street - Thu Jul 10, 5:00AM CDT
Cramer wants to own WhiteWave Foods, likes Johnson & Johnson over Pfizer and wants you to stay away from Gogo.
New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo
PR Newswire - Thu Jul 10, 4:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Novartis AG (NYSE: NVS), GlaxoSmithKline plc (NYSE: GSK) and Endo International PLC (NASDAQ: ENDP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4619-100free.
Jim Cramer's 'Mad Money' Recap: Hunting for Bargains
at The Street - Wed Jul 09, 6:53PM CDT
All you need to do is look at the last quarter's winners, Cramer advises.
Is Pharmacyclics the Next Celgene?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 09, 1:00PM CDT
Pharmacyclics has made a big move in the past two years as investors have become increasingly excited by the potential for Imbruvica, a drug being co-developed with Johnson & Johnson that won its first FDA approval last November. Imbruvica...
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Will Fastenal (FAST) Beat Earnings Estimate in Q2? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 8:00AM CDT
Fastenal Company (FAST) is set to report second-quarter fiscal 2014 results on Jul 11, before the market opens.
Global Electrophysiology Ablation Catheters Market 2014-2018
M2 - Wed Jul 09, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpds69/global) has announced the addition of the "Global Electrophysiology Ablation Catheters Market 2014-2018" report to their offering. Catheter ablation is a minimally invasive procedure used to remove or destroy faulty electrical pathways from sections of the heart that promote irregular cardiac rhythms (also known as cardiac arrhythmias). Cardiac arrhythmias can be of several types, including atrial fibrillation, atrial flutter, and supraventricular tachycardia. Key Regions: - Americas - EMEA - APAC Key Vendors: - Boston Scientific Corp. - Johnson & Johnson - Medtronic Inc. - St. Jude Medical Inc. Other Prominent Vendors: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - VIMECON GmbH Key Market Drivers: - Growing Incidence of Cardiac Arrhythmias. - For a full, detailed list, view the report. Key Market Challenges: - Presence of Substitutes. - For a full, detailed list, view the report. Key Market Trends: - High Adoption of Irrigated-tip EP Ablation Catheters. - For a full, detailed list, view the report. Key Questions Answered in this Report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Technology 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - Advanced Cardiac Therapeutics Inc. - AtriCure Inc. - BIOTRONIK SE & Co. KG - Boston Scientific Corp. - CardioFocus Inc. - Edwards Lifesciences Corp. - Imricor Medical Systems Inc. - Johnson & Johnson - Medtronic Inc. - MicroPort Scientific Corp. - PLC Medical Systems Inc. - St. Jude Medical Inc. - VIMECON GmbH For more information visit http://www.researchandmarkets.com/research/zpds69/global
Fortune 500 Companies Recruit Talent at CAREERS & the disABLED Magazine's Career Expo
PR Newswire - Tue Jul 08, 1:01PM CDT
Equal Opportunity Publications, Inc. (EOP), the leading publisher of diversity recruitment print and online magazines, announces registration is open for CAREERS & the disABLED Magazine's Career Expo, July 18 at the Wyndham New Yorker Hotel in New York City, from 10 a.m. to 3 p.m.
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
